[1]杨菁 郑芬萍.亚临床库欣综合征与代谢异常和结局[J].国际内分泌代谢杂志,2019,39(02):136-140.[doi:10.3760/cma.j.issn.1673-4157.2019.02.016]
　Yang Jing,Zheng Fenping.Subclinical Cushing's syndrome with metabolic disorders and its outcomes[J].International Journal of Endocrinology and Metabolism,2019,39(02):136-140.[doi:10.3760/cma.j.issn.1673-4157.2019.02.016]
点击复制

亚临床库欣综合征与代谢异常和结局()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
39
期数:
2019年02期
页码:
136-140
栏目:
综述
出版日期:
2019-03-20

文章信息/Info

Title:
Subclinical Cushing's syndrome with metabolic disorders and its outcomes
作者:
杨菁 郑芬萍
浙江大学医学院附属邵逸夫医院内分泌科,杭州 310016
Author(s):
Yang Jing;  Zheng Fenping
Department of Endocrinology, Sir Run Run Shaw Hospital Affiliated with Medical School of Zhejiang University, Hangzhou 310016, China
关键词:
亚临床库欣综合征;  代谢异常;  肥胖
Keywords:
Subclinical Cushing's syndrome;  Metabolic disorders;  Obesity
DOI:
10.3760/cma.j.issn.1673-4157.2019.02.016
摘要:
亚临床库欣综合征(SCS)是一种缺乏典型库欣综合征表现的高皮质醇状态。相关研究显示,SCS可能与肥胖、高血压、糖、脂代谢异常及死亡率上升等有密切联系。及早发现SCS,把握手术适应证,降低皮质醇水平,在疾病的临床诊治中显得尤为重要。
Abstract:
Subclinical Cushing's syndrome(SCS)is a state of hypercortisolism in the absence of typical signs of overt cortisol excess. Previous studies have shown that it was associated with obesity, hypertension, abnormal glucose and lipid metabolism, and increased mortality. Early detection of SCS, awareness of surgical indications and reducing cortisol levels are particularly important in the clinical diagnosis and treatment of the diseases.

参考文献/References:

[1] Chiodini I.Clinical review: diagnosis and treatment of subclinical hypercortisolism[J].J Clin Endocrinol Metab,2011,96(5):1223-1236.DOI:10.1210/jc.2010-2722.
[2] Zeiger MA,Thompson GB,Duh QY,et al.The American Association of Clinical Endocrinologists and American Association of End-ocrine Surgeons medical guidelines for the management of adrenal incidentalomas[J].Endocr Pract,2009,15(Suppl 1):1-20.DOI:10.4158/EP.15.S1.1.
[3] Fassnacht M,Arlt W,Bancos I,et al.Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors[J].Eur J Endocrinol,2016,175(2):G1-G34. DOI:10.1530/EJE-16-0467.
[4] Tabarin A,Bardet S,Bertherat J,et al.Exploration and management of adrenal incidentalomas. French Society of Endocrinology Consensus[J].Ann Endocrinol(Paris),2008,69(6):487-500.DOI:10.1016/j.ando.2008.09.003.
[5] Yanase T,Oki Y,Katabami T,et al.New diagnostic criteria of adrenal subclinical Cushing's syndrome:opinion from the Japan End-ocrine Society[J].Endocr J,2018,65(4):383-393.DOI:10.1507/endocrj.EJ17-0456.
[6] Ferraù F,Korbonits M.Metabolic comorbidities in Cushing's syndrome[J].Eur J Endocrinol,2015,173(4):M133-M157.DOI:10.1530/EJE-15-0354.
[7] Anagnostis P,Athyros VG,Tziomalos K,et al.Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis[J].J Clin Endocrinol Metab,2009,94(8):2692-2701.DOI:10.1210/jc.2009-0370.
[8] Caetano MS,Silva Rdo C,Kater CE.Increased diagnostic probability of subclinical Cushing's syndrome in a population sample of overweight adult patients with type 2 diabetes mellitus[J].Arq Bras Endocrinol Metabol,2007,51(7):1118-1127.
[9] Debono M,Prema A,Hughes TJ,et al.Visceral fat accumulation and postdexamethasone serum cortisol levels in patients with adrenal incidentaloma[J].J Clin Endocrinol Metab,2013,98(6):2383-2391.DOI:10.1210/jc.2012-4276.
[10] van Raalte DH,Ouwens DM,Diamant M.Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options[J].Eur J Clin Invest,2009,39(2):81-93.DOI:10.1111/j.1365-2362.2008.02067.x.
[11] Giordano R,Guaraldi F,Berardelli R,et al.Glucose metabolism in patients with subclinical Cushing's syndrome[J].Endocrine,2012,41(3):415-423.DOI:10.1007/s12020-012-9628-9.
[12] Di Dalmazi G,Pasquali R,Beuschlein F,et al.Subclinical hypercortisolism: a state, a syndrome, or a disease [J].Eur J Endocrinol,2015,173(4):M61-M71.DOI:10.1530/EJE-15-0272.
[13] Budyal S,Jadhav SS,Kasaliwal R,et al.Is it worthwhile to screen patients with type 2 diabetes mellitus for subclinical Cushing's syndrome[J].Endocr Connect,2015,4(4):242-248.DOI:10.1530/EC-15-0078.
[14] Androulakis II,Kaltsas GA,Kollias GE,et al.Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion[J].J Clin Endocrinol Metab,2014,99(8):2754-2762.DOI:10.1210/jc.2013-4064.
[15] Ivovi M,Marina LV,Vujovi S,et al.Nondiabetic patients with either subclinical Cushing's or nonfunctional adrenal incidentalomas have lower insulin sensitivity than healthy controls: clinical implications[J].Metabolism,2013,62(6):786-792.DOI:10.1016/j.metabol.2012.12.006.
[16] Cansu GB,At lgan S,Balc MK,et al.Which type 2 diabetes mellitus patients should be screened for subclinical Cushing's syndrome[J].Hormones(Athens),2017,16(1):22-32.DOI:10.14310/horm.2002.1716.
[17] Arnaldi G,Scandali VM,Trementino L,et al.Pathophysiology of dyslipidemia in Cushing's syndrome[J].Neuroendocrinology,2010,92(Suppl 1):86-90.DOI:10.1159/000314213.
[18] Tauchmanovà L,Rossi R,Biondi B,et al.Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk[J].J Clin Endocrinol Metab,2002,87(11):4872-4878.DOI:10.1210/jc.2001-011766.
[19] Tabuchi Y,Otsuki M,Kasayama S,et al.Clinical and endocrinological characteristics of adrenal incidentaloma in Osaka region, Japan[J].Endocr J,2016,63(1):29-35.DOI:10.1507/endocrj.EJ15-0404.
[20] Masserini B,Morelli V,Palmieri S,et al.Lipid abnormalities in patients with adrenal incidentalomas: role of subclinical hypercortisolism and impaired glucose metabolism[J].J Endocrinol Invest,2015,38(6):623-628.DOI:10.1007/s40618-014-0232-0.
[21] De Leo M,Pivonello R,Auriemma RS,et al.Cardiovascular disease in Cushing's syndrome: heart versus vasculature[J].Neuroendocrinology,2010,92(Suppl 1):50-54.DOI:10.1159/000318566.
[22] Pecori Giraldi F,Toja PM,De Martin M,et al.Circadian blood pressure profile in patients with active Cushing's disease and after long-term cure[J].Horm Metab Res,2007,39(12):908-914.DOI:10.1055/s-2007-992813.
[23] Martins LC,Conceição FL,Muxfeldt ES,et al.Prevalence and associated factors of subclinical hypercortisolism in patients with resistant hypertension[J].J Hypertens,2012,30(5):967-973.DOI:10.1097/HJH.0b013e3283521484.
[24] Rossi R,Tauchmanova L,Luciano A,et al.Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features[J].J Clin Endocrinol Metab,2000,85(4):1440-1448.DOI:10.1210/jcem.85.4.6515.
[25] Di Dalmazi G,Vicennati V,Rinaldi E,et al.Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study[J].Eur J Endocrinol,2012,166(4):669-677.DOI:10.1530/EJE-11-1039.
[26] Chiodini I,Albani A,Ambrogio AG,et al.Six controversial issues on subclinical Cushing's syndrome[J].Endocrine,2017,56(2):262-266.DOI:10.1007/s12020-016-1017-3.
[27] Di Dalmazi G,Vicennati V,Garelli S,et al.Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study[J].Lancet Diabetes Endocrinol,2014,2(5):396-405.DOI:10.1016/S2213-8587(13)70211-0.
[28] Debono M,Bradburn M,Bull M,et al.Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas[J].J Clin Endocrinol Metab,2014,99(12):4462-4470.DOI:10.1210/jc.2014-3007.
[29] Terzolo M,Stigliano A,Chiodini I,et al.AME position statement on adrenal incidentaloma[J].Eur J Endocrinol,2011,164(6):851-870.DOI:10.1530/EJE-10-1147.
[30] Morelli V,Reimondo G,Giordano R,et al.Long-term follow-up in adrenal incidentalomas: an Italian multicenter study[J].J Clin Endocrinol Metab,2014,99(3):827-834.DOI:10.1210/jc.2013-3527.
[31] Chiodini I,Morelli V,Salcuni AS,et al.Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism[J].J Clin Endocrinol Metab,2010,95(6):2736-2745.DOI:10.1210/jc.2009-2387.
[32] Toniato A,Merante-Boschin I,Opocher G,et al.Surgical versus conservative management for subclinical Cushing's syndrome in adrenal incidentalomas: a prospective randomized study[J].Ann Surg,2009,249(3):388-391.DOI:10.1097/SLA.0b013e31819a47d2.
[33] Tsuiki M,Tanabe A,Takagi S,et al.Cardiovascular risks and their long-term clinical outcome in patients with subclinical Cushing's syndrome[J].Endocr J,2008,55(4):737-745.
[34] Midorikawa S,Sanada H,Hashimoto S,et al.The improvement of insulin resistance in patients with adrenal incidentaloma by surgicalresection[J].Clin Endocrinol(Oxf),2001,54(6):797-804.

相似文献/References:

[1]白求恩精神研究会内分泌和糖尿病学分会《0年亚临床库欣综合征专家指导建议》编写组.2022年亚临床库欣综合征专家指导建议[J].国际内分泌代谢杂志,2023,43(01):69.[doi:10.3760/cma.j.cn121383-20220930-09061]
　Expert group for Expert consensus on subclinical Cushing's syndrome in China(0).Expert consensus on subclinical Cushing's syndrome in China(2022)[J].International Journal of Endocrinology and Metabolism,2023,43(02):69.[doi:10.3760/cma.j.cn121383-20220930-09061]

备注/Memo

备注/Memo:
通信作者:郑芬萍,Email:3407004@zju.edu.cn
Corresponding author: Zheng Fenping, Email:3407004@zju.edu.cn
更新日期/Last Update: 2019-03-20